Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?

Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16)

You might also be interested in:

ICER’s Updated Assessment of New Targeted Therapies for… June 13, 2018
ICER Releases Updated Report on Targeted Treatments for Plaque… August 5, 2018
ICER Releases Report on Plaque Psoriasis Treatments April 28, 2018
Review of Influence: The Institute for Clinical and Economic Review February 26, 2019
ICER Report Highlights Antiandrogen Therapies for Early-State… October 4, 2018
ICER Releases Report on Therapies for Long-term Prophylaxis HAE November 16, 2018
ICER Releases Evidence Report on CGRP Inhibitors June 1, 2018